- Fibrous optics: Chances look risk-worthy in liver space; BMS rolling the dice
- Amgen's Neupogen faces U.S. headwinds: Earnings
- Lilly deal in hand, drug-device maker Zosano pulls trigger on IPO
- Revived bills impose DEA accountability, cut through regulatory tape
- Ascentage rising: Apoptosis candidate enters clinic in China
SAN FRANCISCO – Although it is still early days, next-generation sequencing (NGS) is being harnessed by researchers and clinicians to help them delve into the complexities of the molecular basis of diseases in order to reveal a patient's genomic profile and how that information relates to the causes of their conditions.
TOKYO – In the nearly 12 years since the completion of the Human Genome Project, next-generation sequencing methods have made genome sequencing both faster and cheaper, leading to massive increases in the numbers of individuals who can be sequenced. Projects have gone from the Human Genome Project, to the 1,000 Genomes Project, to the announcement last week of a 100,000 Genomes Project that plans to start recruiting patients in February 2015. (See BioWorld Today, Dec. 23, 2014.)
READ MORE »- Blocking new target inhibits lung cancer growth, metastasis »
- Synthetic biology used for biocontainment »
- Alzheimer's plaque discovery may clear way to new treatment »
- Keeping synapses cool: Boosting RBM3 to halt neurodegeneration »
- Attractive new anti-TB lead candidate identified »
- Detailed atlas of variants for heart disease gene, protein give new insights »
- Hyperactive bladder drug activates metabolism »
- Ebola vaccines: Both a sprint and a marathon »
- Planting bacteria, sort of, is novel antibiotics discovery method »
- Old dogs and new tricks: The real-world consequences of excluding older adults from drug trialsDecember 10, 2014 | 8:14 PM | Posted by: Marie Powers
- Shoppers, start your engines: BioWorld’s 8th Annual Gift GuideDecember 01, 2014 | 6:12 PM | Posted by: Marie Powers
- Death and taxes: Is the corporate tax rate killing the U.S. economy?October 24, 2014 | 2:54 PM | Posted by: Ann Duncan
- A shot in the dark? ‘Flu’ Manchu-type fears of evil pharma, plus frets over strains and safety, keep too many away from vaccineOctober 07, 2014 | 10:22 PM | Posted by: Randy Osborne
- Emerging biosimilar market knows no parallelSeptember 29, 2014 | 6:15 PM | Posted by: Mari Serebrov
Partners in Focus
